CPSE:NOVO BPharmaceuticals
Is Novo Nordisk’s Alzheimer’s Setback And Obesity Push Altering The Investment Case For CPSE:NOVO B?
Earlier this month, Novo Nordisk presented topline phase 3 Evoke and Evoke+ results for oral semaglutide in Alzheimer’s disease, showing statistically significant but clinically modest biomarker reductions and no success on the primary endpoints, while also completing its US$5.20 billion acquisition of Akero Therapeutics and advancing multiple obesity-drug initiatives.
Although the Alzheimer’s data fell short clinically, the biomarker insights, expanding obesity pipeline, and new...